Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

被引：30

作者：

Kaufman, Jonathan L. ^{[1
]}

Usmani, Saad Z. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Bahlis, Nizar ^{[4
]}

White, Darrell J. ^{[5
,6
]}

Benboubker, Lotfi ^{[7
]}

Cook, Gordon ^{[8
,9
]}

Leiba, Merav ^{[10
]}

Ho, P. Joy

Kim, Kihyun

Takezako, Naoki

Moreau, Philippe ^{[11
]}

Krevvata, Maria ^{[12
]}

Pei, Huiling ^{[13
]}

Ukropec, Jon ^{[14
]}

Renaud, Thomas ^{[15
]}

Trivedi, Sonali ^{[12
]}

Kobos, Rachel ^{[15
]}

Dimopoulos, Meletios A. ^{[16
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[3] Clin Univ Navarra CIMA, IDISNA, CIBERONC, Pamplona, Spain

[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[5] Dalhousie Univ, Halifax, NS, Canada

[6] QEII Hlth Sci Ctr, Halifax, NS, Canada

[7] Ctr Hosp Reg Univ CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France

[8] Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England

[9] Univ Leeds, Leeds, W Yorkshire, England

[10] Ben Gurion Univ Negev, Assuta Univ Hosp, Fac Hlth Sci, Beer Sheva, Israel

[11] Univ Hosp Hotel Dieu, Hematol, Nantes, France

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Global Med Affairs, Horsham, PA USA

[15] Janssen Res & Dev, Raritan, NJ USA

[16] Natl & Kapodistrian Univ Athens, Athens, Greece

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123483

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1866

引用

页数：4

共 50 条

[41] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Pelligra, C.
Guo, S.
Parikh, K.
Zhang, S.
Krotneva, M.
Onyekwere, U.
Clancy, Z.
VALUE IN HEALTH, 2018, 21 : S254 - S254
[42] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Avet-Loiseau, Herve
Casneuf, Tineke
Chiu, Christopher
Laubach, Jacob P.
Lee, Je-Jung
Moreau, Philippe
Plesner, Torben
Nahi, Hareth
Khokhar, Nushmia Z.
Qi, Ming
Schecter, Jordan
Carlton, Victoria
Qin, Xiang
Liu, Kevin
Wu, Kaida
Zhuang, Sen H.
Ahmadi, Tahamtan
Sasser, A. Kate
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[43] Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide-Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Handa, Hiroshi
Suzuki, Kenshi
Chou, Takaaki
Matsushima, Takafumi
BLOOD, 2014, 124 (21)
[44] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
Paulus, Aneel
Alegria, Victoria R.
Laplant, Betsy
Moustafa, Muhamad Alhaj
Chapin, Dustin
Jackson, Keisha
Jani, Prachi
Ahmed, Salman
Edwards, Brett
Manna, Alak
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
BLOOD, 2019, 134
[45] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
Weber, Donna
Knight, Robert
Chen, Christine
Spencer, Andrew
Yu, Zhinuan
Zeldis, Jerome
Olesnyckyj, Marta
Dimopoulos, Meletios
BLOOD, 2007, 110 (11) : 128A - 128A
[46] ADJUSTED COMPARISON OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS LENALIDOMIDE PLUS DEXAMETHASONE (RD) IN SECOND LINE (2L) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS, USING INDIVIDUAL PATIENT LEVEL DATA (IPD) FROM THE CASTOR AND POLLUX TRIALS
Diels, J.
Pfaira, I
Trevor, N.
Anjo, J.
VALUE IN HEALTH, 2019, 22 : S441 - S441
[47] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Jiri Minarik
Tomas Pika
Jakub Radocha
Alexandra Jungova
Jan Straub
Tomas Jelinek
Ludek Pour
Petr Pavlicek
Martin Mistrik
Lucie Brozova
Petra Krhovska
Katerina Machalkova
Pavel Jindra
Ivan Spicka
Hana Plonkova
Martin Stork
Jaroslav Bacovsky
Lenka Capkova
Michal Sykora
Petr Kessler
Lukas Stejskal
Adriana Heindorfer
Jana Ullrychova
Tomas Skacel
Vladimir Maisnar
Roman Hajek
BMC Cancer, 21
[48] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Minarik, Jiri
Pika, Tomas
Radocha, Jakub
Jungova, Alexandra
Straub, Jan
Jelinek, Tomas
Pour, Ludek
Pavlicek, Petr
Mistrik, Martin
Brozova, Lucie
Krhovska, Petra
Machalkova, Katerina
Jindra, Pavel
Spicka, Ivan
Plonkova, Hana
Stork, Martin
Bacovsky, Jaroslav
Capkova, Lenka
Sykora, Michal
Kessler, Petr
Stejskal, Lukas
Heindorfer, Adriana
Ullrychova, Jana
Skacel, Tomas
Maisnar, Vladimir
Hajek, Roman
BMC CANCER, 2021, 21 (01)
[49] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
Weisel, Katja C.
Miguel, Jesus San
Cook, Gordon
Leiba, Merav
Suzuki, Kenshi
Kumar, Shaji
Cavo, Michele
Avet-Loiseau, Herve
Quach, Hang
Hungria, Vania
Lentzsch, Suzanne
Hajek, Roman
Sonneveld, Pieter
Wu, Kaida
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[50] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Plesner, Torben
Dimopoulos, Meletios A.
Oriol, Albert
San-Miguel, Jesus
Bahlis, Nizar J.
Rabin, Neil
Suzuki, Kenshi
Yoon, Sung-Soo
Ben-Yehuda, Dina
Cook, Gordon
Goldschmidt, Hartmut
Grosicki, Sebastian
Qin, Xiang
Fastenau, John
Garvin, Wendy
Carson, Robin
Renaud, Thomas
Gries, Katharine S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 132 - 139

← 1 2 3 4 5 →